Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

A Heratizadeh¹, E Haufe², D Stölzl³, S Abraham⁴, L Heinrich², A Kleinheinz⁵, A Wollenberg⁶, E Weisshaar⁷, M Augustin⁸, F Wiemers⁹, A Zink^{10

11}, R von Kiedrowski¹², M Hilgers¹³, M Worm¹⁴, M Pawlak¹⁵, M Sticherling¹⁶, I Fell¹⁷, C Handrick¹⁸, K Schäkel¹⁹, P Staubach-Renz²⁰, A Asmussen²¹, B Schwarz²², M Bell²³, I Effendy²⁴, T Bieber²⁵, B Homey²⁶, B Gerlach²⁷, E Tchitcherina²⁸, M Stahl²⁹, U Schwichtenberg³⁰, J Rossbacher³¹, P Buck³², M Mempel³³, S Beissert⁴, T Biedermann^{10

11}, S Weidinger^#³, J Schmitt^#², T Werfel^#¹; TREATgermany Study Group

Affiliations

¹ Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
² Center of Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
³ Department of Dermatology and Allergy, Center for Inflammatory Skin Diseases, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁴ Department of Dermatology, University Allergy Center, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
⁵ Clinics for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.
⁶ Clinics and Outpatient Clinics for Dermatology and Allergy, LMU Munich, Munich, Germany.
⁷ Occupational Dermatology, Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
⁸ Insitute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
⁹ Practice Dr. med. Franca Wiemers, Leipzig, Germany.
¹⁰ Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
¹¹ Clinical Unit Allergology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Munich, Germany.
¹² CMSS - Company for Medical Study and Service, Selters/Westerwald, Germany.
¹³ Clinics for Dermatology and Allergy, University Hospital Aachen, Aachen, Germany.
¹⁴ Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹⁵ Practice Dr. med. Anika Hünermund and Mario Pawlak, Heilbad Heiligenstadt, Germany.
¹⁶ Department of Dermatology, University Hospital, Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany.
¹⁷ Hautmedizin Bad Soden, Bad Soden, Germany.
¹⁸ Practice Dr. med. Christiane Handrick, Berlin, Germany.
¹⁹ Department of Dermatology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany.
²⁰ Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany.
²¹ Practice Dermatologie an der Lesum, Bremen, Germany.
²² Practice Dr. med. Beate Schwarz, Langenau, Germany.
²³ Practice Dr. Magnus Bell, Thomas Kaiser, Andernach, Germany.
²⁴ Department of Dermatology, Hospital Rosenhoehe, Bielefeld, Germany.
²⁵ Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.
²⁶ Department of Dermatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany.
²⁷ Practice Dr. med. Beatrice Gerlach, Dresden, Germany.
²⁸ Practice Dr. med. Ekaterina Tchitcherina, Friedberg/Hessen, Germany.
²⁹ Practice Dr. med. Maren Stahl, Osterode, Germany.
³⁰ Hautpraxen Derma-Nord, Bremen, Germany.
³¹ Hautzentrum Friedrichshain, Berlin, Germany.
³² Goldbek Medical, Hamburg, Germany.
³³ Practice Prof. Dr. med. Martin Mempel, Elmshorn, Germany.

^# Contributed equally.

PMID: 31721316
DOI: 10.1111/jdv.16078

Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

A Heratizadeh et al. J Eur Acad Dermatol Venereol. 2020 Jun.

. 2020 Jun;34(6):1263-1272.

doi: 10.1111/jdv.16078. Epub 2020 Feb 13.

Authors

Affiliations

¹ Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
² Center of Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
³ Department of Dermatology and Allergy, Center for Inflammatory Skin Diseases, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁴ Department of Dermatology, University Allergy Center, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
⁵ Clinics for Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany.
⁶ Clinics and Outpatient Clinics for Dermatology and Allergy, LMU Munich, Munich, Germany.
⁷ Occupational Dermatology, Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
⁸ Insitute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
⁹ Practice Dr. med. Franca Wiemers, Leipzig, Germany.
¹⁰ Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
¹¹ Clinical Unit Allergology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Munich, Germany.
¹² CMSS - Company for Medical Study and Service, Selters/Westerwald, Germany.
¹³ Clinics for Dermatology and Allergy, University Hospital Aachen, Aachen, Germany.
¹⁴ Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹⁵ Practice Dr. med. Anika Hünermund and Mario Pawlak, Heilbad Heiligenstadt, Germany.
¹⁶ Department of Dermatology, University Hospital, Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany.
¹⁷ Hautmedizin Bad Soden, Bad Soden, Germany.
¹⁸ Practice Dr. med. Christiane Handrick, Berlin, Germany.
¹⁹ Department of Dermatology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany.
²⁰ Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany.
²¹ Practice Dermatologie an der Lesum, Bremen, Germany.
²² Practice Dr. med. Beate Schwarz, Langenau, Germany.
²³ Practice Dr. Magnus Bell, Thomas Kaiser, Andernach, Germany.
²⁴ Department of Dermatology, Hospital Rosenhoehe, Bielefeld, Germany.
²⁵ Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany.
²⁶ Department of Dermatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany.
²⁷ Practice Dr. med. Beatrice Gerlach, Dresden, Germany.
²⁸ Practice Dr. med. Ekaterina Tchitcherina, Friedberg/Hessen, Germany.
²⁹ Practice Dr. med. Maren Stahl, Osterode, Germany.
³⁰ Hautpraxen Derma-Nord, Bremen, Germany.
³¹ Hautzentrum Friedrichshain, Berlin, Germany.
³² Goldbek Medical, Hamburg, Germany.
³³ Practice Prof. Dr. med. Martin Mempel, Elmshorn, Germany.

^# Contributed equally.

PMID: 31721316
DOI: 10.1111/jdv.16078

Erratum in

CORRIGENDUM: Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD registry TREATgermany.
[No authors listed] [No authors listed] J Eur Acad Dermatol Venereol. 2023 Mar;37(3):633-634. doi: 10.1111/jdv.18838. Epub 2023 Jan 25. J Eur Acad Dermatol Venereol. 2023. PMID: 36695571 No abstract available.

Abstract

Background: The Atopic Dermatitis (AD) TREATgermany registry was initiated by the German Society for Dermatology (DDG) in 2011 to evaluate the 'real-life' situation of health care for patients with AD.

Objectives: Interim data analysis on baseline characteristics as well as current and prescribed systemic treatments of the TREATgermany registry patients.

Methods: Patients (≥18 years) with moderate-to-severe AD [objective (o)SCORAD > 20], or with current or previous anti-inflammatory systemic treatment for AD within 24 months, were included and are followed up over at least 24 months. To assess clinical signs, the eczema area severity index (EASI, 0-72), the oSCORAD (0-83) and the Investigator Global Assessment (IGA; 6-point scale) were used. The disease severity was globally scored by the patients [Patient Global Assessment (PGA); six-step Likert scale]. Disease symptoms were assessed by the patient-oriented eczema measure (POEM, 0-28) and numeric rating scales (NRS, 0-10). Health-related quality of life was measured using the dermatological life quality index (DLQI, 0-30).

Results: A total of 612 patients were recruited across 32 sites between 06/2016 and 01/2019 (mean age: 42.6 ± 14.2 years; mean oSCORAD: 40.8 ± 16.3). The mean POEM score was 16.3 ± 7.5. Pruritus was rated highest among subjective symptoms (NRS: 5.4 ± 2.7). The mean DLQI value was 11.3 ± 7.5. The frequency of arterial hypertension was lower (20.8%) compared with the general population, whilst this was higher for depression (10%). More than 60% of the patients had received systemic glucocorticosteroids, and 36.8% had received cyclosporine A prior to inclusion. Dupilumab was the leading substance documented as either 'current' (12.1%) or 'prescribed' (31.4%) at baseline.

Conclusions: These 'real-life' data clearly demonstrate the substantial disease burden. Most of TREATgermany patients were already treated with or prescribed dupilumab at baseline. Moreover, current findings indicate the urgent need for further alternative agents in order to achieve a perceptible improvement of quality of life of patients with moderate-to-severe AD.

PubMed Disclaimer

References

1. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol 2019; 123: 144-151.
1. Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
1. Schmitt J, Schmitt NM, Kirch W et al. Outpatient care and medical treatment of children and adults with atopic eczema. J Dtsch Dermatol Ges 2009; 7: 345-351.
1. Werfel T, Heratizadeh A, Niebuhr M et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96-103.e9.
1. Reekers R, Busche M, Wittmann M et al. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol 1999; 104: 466-472.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

Sanofi-Aventis Deutschland GmbH

LinkOut - more resources

Full Text Sources
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

Affiliations

Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany

Authors

Affiliations

Erratum in

Abstract

References

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical